Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following total hip or knee arthroplasty
Anderson D R, O'Brien B, Nagpal S, et al
Record ID 31999008416
English
Authors' objectives:
To assess the effectiveness and cost effectiveness of low molecular weight heparin (LMWH) compared with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following total hip or knee arthroplasty.
Authors' recommendations:
There was insufficient evidence to suggest that one of the three LMWH preparations available in Canada was more efficacious or safer than another for prophylaxis of deep vein thrombosis following total hip or knee arthroplasty.
This study reported a trend for a higher rate of major bleeding with use of LMWH than warfarin.
It was determined that there was insufficient evidence to suggest that there was a difference in the effectiveness of LMWH or warfarin prophylaxis for the prevention of symptomatic venous thromboembolic complications following total hip or knee arthroplasty.
For patients undergoing either total hip or total knee arthroplasty, the base-case analysis suggests that deep vein thrombosis prophylaxis with warfarin is dominant over all LMWH regimens, having a lower expected cost per patient, a lower risk of major bleeds and deaths. In this circumstance it is not necessary to calculate cost-effectiveness ratios because the economic attractiveness of the warfarin option is self-evident.
Authors' methods:
Review, Economic evaluation
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
1998
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Arthroplasty, Replacement, Hip
- Arthroplasty, Replacement, Knee
- Costs and Cost Analysis
- Warfarin
- Anticoagulants
- Thrombosis
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.